Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 2/20 | 0.68 |
| ▸ | GBA1 | P04062 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | ACHE | P22303 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.50 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.50 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.50 |
| ▸ | MC4R | P32245 | 1/20 | 0.47 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.47 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21462951 | 1.00 | FUCA1 (0.68) | FUCA1GBA1MAPTACHEALDH1A1 | |
| SCHEMBL7226622 | 1.00 | FUCA1 (0.68) | FUCA1GBA1MAPTACHEALDH1A1 | |
| SCHEMBL21462952 | 1.00 | FUCA1 (0.68) | FUCA1GBA1MAPTACHEALDH1A1 | |
| SCHEMBL12427247 | 1.00 | FUCA1 (0.68) | FUCA1GBA1MAPTACHEALDH1A1 | |
| SCHEMBL6961544 | 1.00 | FUCA1 (0.68) | FUCA1GBA1MAPTACHEALDH1A1 | |
| SCHEMBL21462424 | 1.00 | FUCA1 (0.68) | FUCA1GBA1MAPTACHEALDH1A1 | |
| SCHEMBL915827 | 0.91 | FUCA1 (0.77) | FUCA1GBA1MAPTACHEALDH1A1 | |
| SCHEMBL6962228 | 0.91 | FUCA1 (0.77) | FUCA1GBA1MAPTACHEALDH1A1 | |
| SCHEMBL20901984 | 0.88 | FUCA1 (0.60) | FUCA1GBA1MAPTACHESIGMAR1 | |
| SCHEMBL10041956 | 0.88 | FUCA1 (0.60) | FUCA1GBA1MAPTACHESIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739682-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | Janssen Pharmaceutica NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| EP-4739684-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | Janssen Pharmaceutica NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| WO-2025008060-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | JANSSEN PHARMACEUTICA NV (BE) | 2025-01-09 | — | — | WO | disclosed |
| WO-2025008058-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | JANSSEN PHARMACEUTICA NV (BE) | 2025-01-09 | — | — | WO | disclosed |
| CN-117510465-A | 5, 6-diphenyl pyrazine-2-piperidine compound and preparation method and application thereof | 四川轻化工大学 | 2024-02-06 | — | — | CN | disclosed |
| US-9388196-B2 | Thiazole derivatives as alpha 7 nAChR modulators | LUPIN LIMITED (IN) | 2016-07-12 | — | — | US | disclosed |
| US-20150291617-A1 | Thiazole Derivatives as Alpha 7 nAChR Modulators | LUPIN LIMITED (IN) | 2015-10-15 | — | — | US | disclosed |
| EP-2822946-A1 | THIAZOLE DERIVATIVES AS ALPHA 7 NACHR MODULATORS | Lupin Limited (IN) | 2015-01-14 | — | — | EP | disclosed |
| WO-2013132380-A1 | THIAZOLE DERIVATIVES AS ALPHA 7 NACHR MODULATORS | LUPIN LIMITED (IN) | 2013-09-12 | — | — | WO | disclosed |
| US-8183366-B2 | Chemokine receptor antagonists | NOVARTIS AG (CH) | 2012-05-22 | — | — | US | disclosed |
| US-20070155721-A1 | Chemokine receptor antagonists | NOVARTIS AG (CH) | 2007-07-05 | — | — | US | disclosed |
| CN-1946713-A | Chemokine receptor antagonists | NOVARTIS AG (CH) | 2007-04-11 | — | — | CN | disclosed |
| EP-1720859-A2 | CHEMOKINE RECEPTOR ANTAGONISTS | Novartis AG (CH) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005077932-A2 | CHEMOKINE RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2005-08-25 | — | — | WO | disclosed |
| US-6608078-B2 | Gramnegative bacteria | WOCKHARDT LIMITED (IN) | 2003-08-19 | — | — | US | disclosed |
| US-20020165227-A1 | Antibacterial chiral 8-(substituted piperidino)-benzo [i,j] quinolizines, processes, compositions and methods of treatment | WOCKHARDT RESEARCH CENTER | 2002-11-07 | — | — | US | disclosed |
| WO-2001085728-A2 | ANTIBACTERIAL CHIRAL 8-(SUBSTITUTED PIPERIDINO)-BENZO [I, J] QUINOLIZINES, PROCESSES, COMPOSITIONS AND METHODS OF TREATMENT | WOCKHARDT LIMITED (IN) | 2001-11-15 | — | — | WO | disclosed |
| EP-0106276-B1 | 1,4-DIHYDROPYRIDINE DERIVATIVES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1988-10-26 | — | — | EP | disclosed |
| US-4639522-A | HYPOTENSIVES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1987-01-27 | — | — | US | disclosed |
| EP-0106276-A2 | 1,4-Dihydropyridine derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1984-04-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155721-A1 | Chemokine receptor antagonists | ACKR3, CXCR2, CXCR4 | FUCA1 2460/4885GBA1 1567/4885MAPT 4722/4885 |
| US-20020165227-A1 | Antibacterial chiral 8-(substituted piperidino)-benzo [i,j] quinolizines, processes, compositions and methods of treatment | ALPI, POLR1C, POLI | FUCA1 1778/4885GBA1 866/4885MAPT 1655/4885 |
| US-20150291617-A1 | Thiazole Derivatives as Alpha 7 nAChR Modulators | CHRNA7, CHRM1, CHRM2 | FUCA1 3652/4885GBA1 2458/4885MAPT 331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.